P2Y12 antagonists in non-ST-segment elevation acute coronary syndromes: latest evidence and optimal use-Reference-Cited by-同舟云学术

P2Y12 antagonists in non-ST-segment elevation acute coronary syndromes: latest evidence and optimal use

Published:2015-05-18 Issue:4 Volume:6 Page:204-218
ISSN:2040-6223
Container-title:Therapeutic Advances in Chronic Disease
language:en
Short-container-title:Therapeutic Advances in Chronic Disease

Author:

Norgard Nicholas B.¹,DiNicolantonio James J.²

Affiliation:

1. University at Buffalo School of Pharmacy & Pharmaceutical Sciences, NYS Center of Excellence, Bioinformatics & Life Sciences, 701 Ellicott St, B3-322, Buffalo, NY 14203, USA

2. Department of Preventive Cardiology, Saint Luke’s Mid America Heart Institute, Kansas City, MO, USA

Abstract

Dual antiplatelet therapy (DAPT), which includes the combination of aspirin and a P2Y12 platelet receptor inhibitor, is a well-established antiplatelet regimen in the treatment of patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS). Three P2Y12 inhibitor options (clopidogrel, prasugrel and ticagrelor) are currently available, all having different efficacy and safety profiles along with contrasting contraindications, special warnings and precautions for use. This review compares and contrasts the unique P2Y12 antagonists in the NSTE-ACS setting, covering the latest evidence and their optimal use.

Publisher

SAGE Publications

Subject

Medicine (miscellaneous)

Link

http://journals.sagepub.com/doi/pdf/10.1177/2040622315584113

Reference117 articles.

1. Clopidogrel 150 mg/day to Overcome Low Responsiveness in Patients Undergoing Elective Percutaneous Coronary Intervention

2. Prasugrel resistance: Fact or fiction

3. Ticagrelor Versus Prasugrel in Acute Coronary Syndrome Patients With High On-Clopidogrel Platelet Reactivity Following Percutaneous Coronary Intervention

4. 2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes

5. Variability in Responsiveness to Oral Antiplatelet Therapy

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dosage optimization of clopidogrel via a precision medicine approach: the way forward;Pharmacogenomics;2022-02

2. Comparative Effectiveness of Oral Antiplatelet Agents in Patients with Acute Coronary Syndrome;Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy;2017-07-18

3. Is there an optimal duration of Dual Antiplatelet Therapy after Drug-Eluting Stent Implantation?;EMJ Interventional Cardiology;2017-07-04

4. Acquired Hemophilia a may be Associated with Ticagrelor Therapy in a 52-Year-Old Man after a Recent Percutaneous Transluminal Coronary Angioplasty;Clinical Medicine Insights: Case Reports;2016-01